6926-09-6

Basic information

• Product Name: Boc-Glycine hydrazide
• Synonyms: N-TERT-BUTOXYCARBONYLGLYCYLHYDRAZIDE;BOC-GLYCINE HYDRAZIDE;BUTTPARK 77\04-08;Butoxycarbonylglycine hydrazide;Boc-Glycinehydrazide，98%;Hydrazinocarbonylmethyl-carbamic acid tert-butyl ester;2-Aminoacetohydrazide, 2-BOC protected;tert-Butyl (2-hydrazino-2-oxoethyl)carbamate, 2-[(tert-Butoxycarbonyl)amino]acetohydrazide
• CAS NO: 6926-09-6
• Molecular Formula: C₇H₁₅N₃O₃
• Molecular Weight: 189.21
• Mol File: 6926-09-6.mol

Chemical Properties

• Melting Point: 111-115
• Boiling Point: 386.5oC at 760 mmHg
• Flash Point: 187.5oC
• Appearance: /
• Density: 1.139g/cm3
• Vapor Pressure: 3.54E-06mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.40±0.46(Predicted)
• CAS DataBase Reference: Boc-Glycine hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Glycine hydrazide(6926-09-6)
• EPA Substance Registry System: Boc-Glycine hydrazide(6926-09-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 6926-09-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Boc-Glycine hydrazide is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its application in this industry is due to its ability to react with other compounds to form new molecules with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, Boc-Glycine hydrazide is utilized as an intermediate for the production of a wide range of organic compounds. Its use in this industry is attributed to its reactivity and capacity to form diverse chemical structures, which can be further modified for specific applications.
Used in Laboratory Research and Development:
Boc-Glycine hydrazide is also employed in laboratory research and development processes, where it is used to explore new chemical reactions and synthesize novel compounds. Its application in this context is due to its potential to contribute to the discovery of new drugs and materials with various properties and functions.
Used in Chemical Production Process:
Lastly, Boc-Glycine hydrazide is used in the chemical production process, where it plays a role in the manufacturing of various chemicals and materials. Its use in this industry is a result of its ability to improve the efficiency and effectiveness of chemical synthesis, leading to the production of high-quality products.

Synthesis

N-Protected Hydrazides 2a-l; General Procedure The protected amino acid 1 (2 equiv) and EDAC (2 equiv) were dissolved in the minimum amount of CH2Cl2 at 0 °C. The mixture was stirred at 0 °C for 2 h. PhthNNH2 (1 equiv) was added and the mixture was stirred at 0 °C for 1 h and then at r.t. overnight. Distillation of the solvent under reduced pressure gave a product which was dissolved in EtOAc and washed successively with 1 M KHSO4, sat. aq NaHCO3, and brine. The organic layer was then dried (Na2SO4), filtered, and concentrated in vacuo. The residue was precipitated with Et2O to yield compound 2. If necessary, the residue was purified by column chromatography (silica gel, hexane- EtOAc, 3:7 to 7:3). Compounds 4a-l; General Procedure Aminomethylated polystyrene resin (3 equiv; 1.1 mmol/g, 100-200 mesh) was conditioned for 10 min at r.t. in CH2Cl2. Then 2 (1 equiv) was added, and the mixture was slowly stirred for 24 h at r.t. The mixture was filtered and the solvent was evaporated in vacuo to give product 4. Compound 4h, yield 89%.

InChI:InChI=1/C7H15N3O3/c1-7(2,3)13-6(12)9-4-5(11)10-8/h4,8H2,1-3H3,(H,9,12)(H,10,11)

Upstream product

• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 
• 83316-95-4 2-oxo-2-phenylethyl 2-(tert-butoxycarbonylamino)acetate 

Downstream Products

• 1188405-97-1 C₂₇H₃₆N₆O₆ 
• 67585-87-9 Boc-Gly-AzaPhe-Leu-OMe 
• 716329-43-0 tert-butyl ((1,3,4-oxadiazol-2-yl)methyl)carbamate 

Relevant articles and documents

Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer in Vitro and in Vivo

Clinical and preclinical data reveal that RECQL5 protein overexpression in breast cancer was strongly correlated with poor prognosis, survival, and therapeutic resistance. In the current investigation, we report design, synthesis, and specificity of a small molecule, 4a, which can preferentially kill RECQL5-expressing breast cancers but not RECQL5 knockout. Our stringent analysis showed that compound 4a specifically sensitizes RECQL5-expressing cancers, while it did not have any effect on other members of DNA RECQL-helicases. Integrated approaches of organic synthesis, biochemical, in silico molecular simulation, knockouts, functional mutation, and rescue experiments showed that 4a potently inhibits RECQL5-helicase activity and stabilizes RECQL5-RAD51 physical interaction, leading to impaired HRR and preferential killing of RECQL5-expressing breast cancer. Moreover, 4a treatment led to the efficient sensitization of cisplatin-resistant breast cancers but not normal mammary epithelial cells. Pharmacologically, compound 4a was orally effective in reducing the growth of RECQL5-expressing breast tumors (human xenograft) in NUDE-mice with no appreciable toxicity to the vital organs.

?-LACTAMASE INHIBITOR AND USE THEREOF

Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

CHEMICAL COMPOUNDS AS ANTIBIOTICS

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p? q, L, ?, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Consecutive hydrazino-Ugi-azide reactions: Synthesis of acylhydrazines bearing 1,5-disubstituted tetrazoles

Isocyanide-based multicomponent reactions (IMCRs) allow the construction of relatively complex molecules through a one-pot synthesis. The combination of IMCRs in a consecutive or sequential fashion further extends the complexity of the molecules obtained. Herein, we report the efficient application of this approach to the synthesis of acylhydrazines bearing 1,5-disubstituted tetrazoles. Our strategy was accomplished in only three steps: first, a one-pot hydrazino-Ugi-azide four-component reaction; second a hydrazinolysis and finally an additional hydrazino-Ugi-azide reaction. This sequence provides the title compounds in moderate to excellent yields. The products synthesized herein contain functional groups within their structures that can be easily modified to obtain new acylhydrazino 1,5-disubstituted tetrazoles.

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta -lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Synthesis of acylhydrazino-peptomers, a new class of peptidomimetics, by consecutive Ugi and hydrazino-Ugi reactions

Herein we describe a versatile approach for the synthesis of acylhydrazino-peptomers, a new class of peptidomimetics. The key idea in this approach is based on a simple route using a one-pot hydrazino-Ugi four-component reaction followed by a hydrazinolysis or hydrolysis reaction and subsequent hydrazino-Ugi reaction or classical Ugi reaction for the construction of acyclic acylhydrazino-peptomers. The consecutive multicomponent reactions produced a variety of acylhydrazino-peptomers in moderate to excellent yields (47-90%). These compounds are multifunctional intermediates that can be further functionalized to obtain new peptidomimetics with potential biological activity.